Management of diabetic dyslipidemia: Need for reappraisal of the goals

American Journal of Cardiovascular Drugs

Volumn 5, Issue 2, 2005, Pages 83-91

  Khera, Amit ^a   McGuire, Darren K ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMINOTRANSFERASE; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CHOLESTEROL; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN; METFORMIN; NICOTINIC ACID; NICOTINIC ACID DERIVATIVE; OMEGA 3 FATTY ACID; PIOGLITAZONE; PLACEBO; PRAVASTATIN; ROSIGLITAZONE; SIMVASTATIN; TRIACYLGLYCEROL; TROGLITAZONE; UNINDEXED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIET THERAPY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DYSLIPIDEMIA; EXERCISE; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; META ANALYSIS; MONOTHERAPY; MORTALITY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CLOFIBRIC ACID; DIABETES COMPLICATIONS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 14944371378     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200505020-00002     Document Type: Review

References (106)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21 (9): 1414-31
2. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population 1971-1993. Diabetes Care 1998; 21 (7): 1138-45
3. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study. JAMA 1979; 241 (19): 2035-8
4. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16 (2): 434-44
5. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339 (4): 229-34
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285 (19): 2486-97
7. Creager MA, Luscher TF, Cosentino F, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy. Part I. Circulation 2003; 108 (12): 1527-32
8. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287 (19): 2570-81
9. Ayyobi AF, Brunzell JD. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. Am J Cardiol 2003; 92 (4A): 27J-33J
10. Goldberg IJ. Clinical review 124: diabetic dyslipidemia. Causes and consequences. J Clin Endocrinol Metab 2001; 86 (3): 965-71
11. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT-LLA). A multicentre randomised controlled trial. Lancet 2003; 361 (9364): 1149-58
12. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20 (4): 614-20
13. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randonrised placebo-controlled trial. Lancet 2004; 364: 685-96
14. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999; 159 (22): 2661-7
15. Keech A, Colquhoun D, Best J, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003; 26 (10): 2713-21
16. The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention with Pravastatin in Ischaemic Disease Study Group. N Engl J Med 1998; 339: 1349-57
17. Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002; 105 (12): 1424-8
18. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density tipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341 (6): 410-8
19. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Heart Protection Study Collaborative Group. Lancet 2003; 361: 2005-16
20. Kelley DE, Simoneau JA. Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. J Clin Invest 1994; 94 (6): 2349-56
21. Cummings MH, Watts GF, Umpleby AM, et al. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia 1995; 38 (8): 959-67
22. Taghibiglou C, Carpentier A, Van Iderstine SC, et al. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance: evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J Biol Chem 2000; 275 (12): 8416-25
23. Yost TJ, Froyd KK, Jensen DR, et al. Change in skeletal muscle lipoprotein lipase activity in response to insulin/glucose in non-insulin-dependent diabetes mellitus. Metabolism 1995; 44 (6): 786-90
24. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3 (2): 213-9
25. Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97 (11): 1029-36
26. Lamarche B, Despres JP, Moorjani S, et al. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study). Am J Cardiol 1995; 75 (17): 1189-95
27. Sniderman AD, Furberg CD, Keech A, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003; 361 (9359): 777-80
28. Hayek T, Azrolan N, Verdery RB, et al. Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism: studies in transgenic mice. J Clin Invest 1993; 92 (3): 1143-52
29. Sibley SD, Palmer JP, Hirsch IB, et al. Visceral obesity, hepatic lipase activity, and dyslipidemia in type 1 diabetes. J Clin Endocrinol Metab 2003; 88 (7): 3379-84
30. Gowri MS, Van der Westhuyzen DR, Bridges SR, et al. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol 1999; 19 (9): 2226-33
31. Kannel WB, Neaton JD, Wentworth D, et al. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT: Multiple Risk Factor Intervention Trial. Am Heart J 1986; 112 (4): 825-36
32. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986; 256 (20): 2835-8
33. de Graaf J, Hak-Lemmers HL, Hectors MP, et al. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subtraction in healthy subjects. Arterioscler Thromb 1991; 11 (2): 298-306
34. Vaisanen S, Baumstark MW, Penttila I, et al. Small, dense LDL particle concentration correlates with plasminogen activator inhibitor type-1 (PAI-1) activity. Thromb Haemost 1997; 78 (6): 1495-9
35. Sattar N, Petrie JR, Jaap AJ. The atherogenic, lipoprotein phenotype and vascular endothetial dysfunction. Atherosclerosis 1998; 138 (2): 229-35
36. Bjornheden T, Babyi A, Bondjers G, et al. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 1996; 123 (1-2): 43-56
37. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95 (1): 69-75
38. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996; 276 (11): 875-81
39. Chapman MJ, Caslake M, Packard C, et al. New dimension of statin action on ApoB atherogenicity. Clin Cardiol 2003; 26 (1 Suppl. 1): I7-10
40. Sowers JR. Effects of statins on the vasculature: implications for aggressive lipid management in the cardiovascular metabolic syndrome. Am J Cardiol 2003; 91 (4A): 14B-22B
41. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998; 98 (23): 2513-9
42. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279 (20): 1615-22
43. Sever PS, Dahlof B, Poulter NR, et al. ASCOT-LLA: questions about the benefits of atorvastatin (letter). Lancet 2003; 361: 1986-7
44. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326): 7-22
45. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98 (19): 2088-93
46. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density tipoprotein intervention trial (VA-HIT). Arch Intern Med 2002; 162 (22): 2597-604
47. Frick MH, Elo O, Happa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45
48. The Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357 (9260): 905-10
49. The Bezafibrate Infarction Prevention (BIP) Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102 (1): 21-7
50. Koskinen P, Manttari M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15: 820-5
51. Guerin M, Bruckert E, Dolphin PJ, et al. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996; 16 (6): 763-72
52. Yuan J, Tsai MY, Hunninghake DB. Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis 1994; 110 (1): 1-11
53. McKenney JM, McCormick LS, Schaefer EJ, et al. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 2001; 88 (3): 270-4
54. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002; 162 (14): 1568-76
55. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990; 264 (6): 723-6
56. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study. A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000; 284 (10): 1263-70
57. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231 (4): 360-81
58. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8 (6): 1245-55
59. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001; 35 (7-8): 908-17
60. Kyrklund C, Backman JT, Kivisto KT, et al. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001; 69 (5): 340-5
61. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005 Jan; 95 (1): 120-2
62. Vega GL, Ma PT, Cater NB, et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2003; 91 (8): 956-60
63. Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002; 25 (7): 1198-202
64. Wake Forest University School of Medicine, Public Health Sciences Department. Action to control cardiovascular risk in diabetes [online]. Available from URL: http://www.accordtrial.org [Accessed 2004 Jun 28]
65. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345 (22): 1583-92
66. Zhao XQ, Morse JS, Dowdy AA, et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol 2004; 93 (3): 307-12
67. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110: 3512-7
68. Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet 2000; 355 (9208): 1008-10
69. Plutzky J. The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. Am J Cardiol 2003; 92 (4A): 34J-41J
70. Freed MI, Ratner R, Marcovina SM, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002; 90 (9): 947-52
71. Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24 (2): 308-15
72. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002; 25 (4): 708-11
73. Herz M, Johns D, Reviriego J, et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther 2003; 25 (4): 1074-95
74. Sobel BE, Frye R, Detre KM. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation 2003; 107 (4): 636-42
75. Andrews TC, Ballantyne CM, Hsia JA, et al. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001; 111 (3): 185-91
76. Ballantyne CM, Houri J, Notarbartolo, A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107 (19): 2409-15
77. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40 (12): 2125-34
78. Stroup JS, Kane MP, Busch RS. The antilipidemic effects of ezetimibe in patients with diabetes. Diabetes Care 2003; 26 (10): 2958-9
79. Petersen M, Pedersen H, Major-Pedersen A, et al. Effect of fish oil versus corn oil supplementation on LDL and HDL subclasses in type 2 diabetic patients. Diabetes Care 2002; 25 (10): 1704-8
80. Friday KE, Childs MT, Tsunehara CH, et al. Elevated plasma glucose and lowered triglyceride levels from omega-3 fatty acid supplementation in type II diabetes. Diabetes Care 1989; 12 (4): 276-81
81. Montori VM, Farmer A, Wollan PC, et al. Fish oil supplementation in type 2 diabetes: a quantitative systematic review. Diabetes Care 2000; 23 (9): 1407-15
82. Glauber H, Wallace P, Griver K, et al. Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann Intern Med 1988; 108 (5): 663-8
83. Friedberg CE, Janssen MJ, Heine RJ, et al. Fish oil and glycemic control in diabetes: a meta-analysis. Diabetes Care 1998; 21 (4): 494-500
84. Hu FB, Cho E, Rexrode KM, et al. Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation 2003; 107 (14): 1852-7
85. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus: the Multicenter Metformin Study Group. N Engl J Med 1995; 333 (9): 541-9
86. Taskinen MR, Kuusi T, Helve E, et al. Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 1988; 8 (2): 168-77
87. Romano G, Patti L, Innelli F, et al. Insulin and sulfonylurea therapy in NIDDM patients: are the effects on lipoprotein metabolism different even with similar blood glucose control? Diabetes 1997; 46 (10): 1601-6
88. Duvillard L, Pont F, Florentin E, et al. Significant improvement of apolipoprotein B-containing lipoprotein metabolism by insulin treatment in patients with non-insulin-dependent diabetes mellitus. Diabetologia 2000; 43 (1): 27-35
89. Rivellese AA, Patti L, Romano G, et al. Effect of insulin and sulfonylurea therapy, at the same level of blood glucose control, on low density lipoprotein subfractions in type 2 diabetic patients. J Clin Endocrinol Metab 2000; 85 (11): 4188-92
90. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published erratum appears in Lancet 1999; 354 (9178): 602]. Lancet 1998; 352 (9131): 837-53
91. Yamanouchi K, Shinozaki T, Chikada K, et al. Daily walking combined with diet therapy is a useful means for obese NIDDM patients not only to reduce body weight but also to improve insulin sensitivity. Diabetes Care 1995; 18 (6): 775-8
92. Devlin JT. Effects of exercise on insulin sensitivity in humans. Diabetes Care 1992; 15 (11): 1690-3
93. Boudou P, de Kerviler E, Erlich D, et al. Exercise training-induced triglyceride lowering negatively correlates with DHEA levels in men with type 2 diabetes. Int J Obes Relat Metab Disord 2001; 25 (8): 1108-12
94. Hamdy O, Goodyear LJ, Horton ES. Diet and exercise in type 2 diabetes mellitus. Endocrinol Metab Clin North Am 2001; 30 (4): 883-907
95. Kishimoto H, Taniguchi A, Fukushima M, et al. Effect of short-term low-intensity exercise on insulin sensitivity, insulin secretion, and glucose and lipid metabolism in non-obese Japanese type 2 diabetic patients. Horm Metab Res 2002; 34 (1): 27-31
96. Wei M, Gibbons LW, Kampert JB, et al. Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes. Ann Intern Med 2000; 132 (8): 605-11
97. Tanasescu M, Leitzmann MF, Rimm EB, et al. Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes. Circulation 2003; 107 (19): 2435-9
98. Hu FB, Stampfer MJ, Solomon C, et al. Physical activity and risk for cardiovascular events in diabetic women. Ann Intern Med 2001; 134 (2): 96-105
99. Grundy SM, Garber A, Goldberg R, et al. Prevention Conference VI: diabetes and Cardiovascular Disease. Writing Group IV: lifestyle and medical management of risk factors. Circulation 2002; 105 (18): e153-158
100. Frost G, Leeds AA, Dore CJ, et al. Glycaemic index as a determinant of serum HDL-cholesterol concentration. Lancet 1999; 353 (9158): 1045-8
101. Jarvi AE, Karlstrom BE, Granfeldt YE, et al. Improved glycemic control and lipid profile and normalized fibrinolytic activity on a low-glycemic index diet in type 2 diabetic patients. Diabetes Care 1999; 22 (1): 10-8
102. Grundy SM. The optimal ratio of fat-to-carbohydrate in the diet. Annu Rev Nutr 1999; 19: 325-41
103. Gonzelez C, Stern MP, Mitchell BD, et al. Clinical characteristics of type II diabetic subjects consuming high versus low carbohydrate diets in Mexico City and San Antonio, Texas. Diabetes Care 1994; 17 (5): 397-404
104. Garg A, Bantle JP, Henry RR, et al. Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. JAMA 1994; 271 (18): 1421-8
105. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110 (2): 227-39
106. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004 Jan; 27 Suppl. 1: S15-35